Valuation: Vectus Biosystems Limited

Market Cap 4.66M 3.28M 2.94M 2.7M 2.45M 4.58M 312M 32.23M 12.94M 164M 12.31M 12.05M 517M P/E 2025
-1.2x
P/E 2026 4.45x
Enterprise Value 1.69M 1.19M 1.07M 982K 889K 1.66M 113M 11.71M 4.7M 59.52M 4.47M 4.38M 188M EV / Sales 2025
4.35x
EV / Sales 2026 1.71x
Free-Float
49.49%
Yield 2025 *
-
Yield 2026 -
1 day-5.06%
1 week-16.67%
Current month-31.82%
1 month-31.82%
3 months-42.31%
6 months-37.50%
Current year-58.33%
1 week 0.08
Extreme 0.075
0.09
1 month 0.08
Extreme 0.075
0.11
Current year 0.08
Extreme 0.075
0.22
1 year 0.08
Extreme 0.075
0.46
3 years 0.04
Extreme 0.037
0.46
5 years 0.04
Extreme 0.037
1.7
10 years 0.04
Extreme 0.037
2.2
Manager TitleAgeSince
Chief Executive Officer - 07/05/2026
Corporate Secretary - 09/07/2015
Director TitleAgeSince
Director/Board Member - 12/12/2005
Chairman - 31/08/2018
Director/Board Member - 20/12/2024
Change 5-day change 1-year change 3-year change Capi.($)
-5.06%-16.67%-34.78%-79.17% 3.28M
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average -0.20%+5.12%+39.60%+177.77% 39.43B
Weighted average by Cap. +0.18%+5.44%+48.50%+186.13%

Financials

2025 2026
Net sales 478K 336K 301K 277K 251K 469K 31.94M 3.3M 1.33M 16.8M 1.26M 1.24M 52.99M 2.77M 1.95M 1.74M 1.6M 1.45M 2.72M 185M 19.12M 7.68M 97.23M 7.31M 7.15M 307M
Net income -1.78M -1.25M -1.12M -1.03M -933K -1.74M -119M -12.28M -4.93M -62.45M -4.69M -4.59M -197M 1.56M 1.1M 982K 903K 819K 1.53M 104M 10.77M 4.32M 54.77M 4.12M 4.03M 173M
Net Debt -50.99K -35.87K -32.13K -29.55K -26.78K -50.05K -3.41M -352K -141K -1.79M -135K -132K -5.65M -2.97M -2.09M -1.87M -1.72M -1.56M -2.92M -198M -20.53M -8.24M -104M -7.84M -7.67M -329M
Projected Income Statement - Annual - Vectus Biosystems Limited
Logo Vectus Biosystems Limited
Vectus Biosystems Limited is an Australia-based drug discovery and development company. The Company focuses on medical research and development. It is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The Company has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.
Employees
-
Date Price Change Volume
30/10/26 $0.0750 -5.06% 15,000
28/10/26 $0.0790 -1.25% 73,149
27/10/26 $0.0800 -11.11% 111,129
26/10/26 $0.0900 0.00% 1,800
23/10/26 $0.0900 0.00% 9,556